Nitrogén Monoxid Messer (Nitric Oxide)

The nitric oxide released from the inhaled gas activates soluble guanylate cyclase in pulmonary smooth‑muscle cells. This increases cyclic GMP levels, causing relaxation of the muscle and selective vasodilation of the pulmonary circulation, thereby reducing pulmonary arterial pressure without major systemic effects.

The dosage of Nitrogén Monoxid Messer is determined by the prescribing clinician based on the patient’s condition, severity of pulmonary hypertension, and response to therapy. The prescriber sets the appropriate inhaled concentration and duration for each individual case.

Safety data for inhaled nitric oxide in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with systemic vasodilators, inhaled nitric oxide offers selective pulmonary vasodilation, minimizing systemic hypotension. Unlike oral phosphodiesterase‑5 inhibitors, its effect is rapid and can be titrated in real time, making it useful for acute management and peri‑operative settings.

The product should be stored at ambient temperature, away from direct sunlight and moisture. Keep the gas container sealed in its original packaging until use, and follow any manufacturer‑specified handling instructions to maintain gas purity.

Nitrogén Monoxid Messer is administered via a calibrated inhalation system that delivers a controlled concentration of nitric oxide gas directly to the patient’s airway. Administration is performed by qualified healthcare personnel in a monitored clinical setting.

The most serious risks include methemoglobinemia, which reduces oxygen‑carrying capacity of blood, and rebound pulmonary hypertension if the therapy is stopped abruptly. Monitoring methemoglobin levels and tapering the dose when discontinuing are essential safety measures.

Patients with severe anemia, known hypersensitivity to nitric oxide, or those receiving contraindicated medications such as methylene blue should avoid this therapy. Additionally, individuals with uncontrolled systemic hypotension or certain congenital heart defects may be unsuitable candidates.